Skip to content
TrackPodcasts
businessNov 17, 20254:26pending

Pre-Session Views

Al Ahly Pharos

About this episode

In today's views

  • Strategy | Nile Pharma (NIPH) is closing in on Rameda and this may trigger arbitrage opportunities
  • ISPH | The decline in ISPH stock price yesterday confirms that 3Q25 results are strong.
  • VALU | 9M25 bottom line is consistent with a full year target of EGP750 million 
  • ETEL | Share price is approaching our FV upper end of EGP73/share, what is incorporated and what’s not?
  • MFPC | 3Q soft on volumes and  FX, but gas policy shield supports premium  
  • EGCH | Resilient margins supported by pricing; operational recovery yet to show
  • EKHO | 3Q25: On track for full-year guidance; 4Q25 poised for stronger finish
  • LCSW | Economies of scale drive strong 3Q25; weak 4Q25 to derail EGP360m earnings target
  • ORWE | Improved 3Q25 puts ORWE on track to meet revised 2025e guidance

Get every episode summarized

Each time Al Ahly Pharos publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Pre-Session Views

Al Ahly Pharos

0:00
4:26

More episodes

More from Al Ahly Pharos

View all episodes →